Clinicopathological characteristics and prognosis of uterine sarcoma: a 10-year retrospective single-center study in China.
Chinese patients
Clinicopathological characteristics
Prognosis
Survival
Uterine sarcoma
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
05 Jul 2024
05 Jul 2024
Historique:
received:
11
04
2024
accepted:
21
06
2024
medline:
6
7
2024
pubmed:
6
7
2024
entrez:
5
7
2024
Statut:
epublish
Résumé
Uterine sarcoma is a rare and heterogeneous gynecological malignancy characterized by aggressive progression and poor prognosis. The current study aimed to investigate the relationship between clinicopathological characteristics and the prognosis of uterine sarcoma in Chinese patients. In this single-center retrospective study, we reviewed the medical records of 75 patients with histologically verified uterine sarcoma treated at the First Affiliated Hospital of Xi'an Jiaotong University between 2011 and 2020. Information on clinical characteristics, treatments, pathology and survival was collected. Progression-free survival (PFS) and overall survival (OS) were visualized in Kaplan-Meier curves. Prognostic factors were identified using the log-rank test for univariate analysis and Cox-proportional hazards regression models for multivariate analysis. The histopathological types included 36 endometrial stromal sarcomas (ESS,48%), 33 leiomyosarcomas (LMS,44%) and 6 adenosarcomas (8%). The mean age at diagnosis was 50.2 ± 10.7 years. Stage I and low-grade accounted for the majority. There were 26 recurrences and 25 deaths at the last follow-up. The mean PFS and OS were 89.41 (95% CI: 76.07-102.75) and 94.03 (95% CI: 81.67-106.38) months, respectively. Univariate analysis showed that > 50 years, post-menopause, advanced stage, ≥ 1/2 myometrial invasion, lymphovascular space invasion and high grade were associated with shorter survival (P < 0.05). Color Doppler flow imaging positive signals were associated with shorter PFS in the LMS group (P = 0.046). The ESS group had longer PFS than that of the LMS group (99.56 vs. 76.05 months, P = 0.043). The multivariate analysis showed that post-menopause and advanced stage were independent risk factors of both PFS and OS in the total cohort and LMS group. In the ESS group, diagnosis age > 50 years and high-grade were independent risk factors of PFS, while high-grade and lymphovascular space invasion were independent risk factors of OS. In Chinese patients with uterine sarcoma, post-menopause and advanced stage were associated with a significantly poorer prognosis. The prognosis of ESS was better than that of LMS. Color Doppler flow imaging positive signals of the tumor helped to identify LMS, which needs to be further tested in a larger sample in the future.
Sections du résumé
BACKGROUND
BACKGROUND
Uterine sarcoma is a rare and heterogeneous gynecological malignancy characterized by aggressive progression and poor prognosis. The current study aimed to investigate the relationship between clinicopathological characteristics and the prognosis of uterine sarcoma in Chinese patients.
METHODS
METHODS
In this single-center retrospective study, we reviewed the medical records of 75 patients with histologically verified uterine sarcoma treated at the First Affiliated Hospital of Xi'an Jiaotong University between 2011 and 2020. Information on clinical characteristics, treatments, pathology and survival was collected. Progression-free survival (PFS) and overall survival (OS) were visualized in Kaplan-Meier curves. Prognostic factors were identified using the log-rank test for univariate analysis and Cox-proportional hazards regression models for multivariate analysis.
RESULTS
RESULTS
The histopathological types included 36 endometrial stromal sarcomas (ESS,48%), 33 leiomyosarcomas (LMS,44%) and 6 adenosarcomas (8%). The mean age at diagnosis was 50.2 ± 10.7 years. Stage I and low-grade accounted for the majority. There were 26 recurrences and 25 deaths at the last follow-up. The mean PFS and OS were 89.41 (95% CI: 76.07-102.75) and 94.03 (95% CI: 81.67-106.38) months, respectively. Univariate analysis showed that > 50 years, post-menopause, advanced stage, ≥ 1/2 myometrial invasion, lymphovascular space invasion and high grade were associated with shorter survival (P < 0.05). Color Doppler flow imaging positive signals were associated with shorter PFS in the LMS group (P = 0.046). The ESS group had longer PFS than that of the LMS group (99.56 vs. 76.05 months, P = 0.043). The multivariate analysis showed that post-menopause and advanced stage were independent risk factors of both PFS and OS in the total cohort and LMS group. In the ESS group, diagnosis age > 50 years and high-grade were independent risk factors of PFS, while high-grade and lymphovascular space invasion were independent risk factors of OS.
CONCLUSION
CONCLUSIONS
In Chinese patients with uterine sarcoma, post-menopause and advanced stage were associated with a significantly poorer prognosis. The prognosis of ESS was better than that of LMS. Color Doppler flow imaging positive signals of the tumor helped to identify LMS, which needs to be further tested in a larger sample in the future.
Identifiants
pubmed: 38970112
doi: 10.1186/s13000-024-01517-x
pii: 10.1186/s13000-024-01517-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
94Informations de copyright
© 2024. The Author(s).
Références
Desar IME, Ottevanger PB, Benson C, van der Graaf WTA. Systemic treatment in adult uterine sarcomas. Crit Rev Oncol Hematol. 2018;122:10–20.
doi: 10.1016/j.critrevonc.2017.12.009
pubmed: 29458779
Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. Int J Gynaecol Obstet. 2018;143(Suppl 2):51–8.
doi: 10.1002/ijgo.12613
pubmed: 30306577
Hosh M, Antar S, Nazzal A, Warda M, Gibreel A, Refky B. Uterine sarcoma: analysis of 13,089 cases based on Surveillance, Epidemiology, and end results database. Int J Gynecol Cancer. 2016;26(6):1098–104.
doi: 10.1097/IGC.0000000000000720
pubmed: 27177280
Santos P, Cunha TM. Uterine sarcomas: clinical presentation and MRI features. Diagn Interv Radiol. 2015;21(1):4–9.
doi: 10.5152/dir.2014.14053
pubmed: 25347940
Lentz SE, Zaritsky E, Tucker LY, Lee C, Lazo IM, Niihara A, Yamamoto M, Raine-Bennett T. Prediction of Occult Uterine Sarcoma before Hysterectomy for women with leiomyoma or abnormal bleeding. J Minim Invasive Gynecol. 2020;27(4):930–e937931.
doi: 10.1016/j.jmig.2019.07.017
pubmed: 31352067
Wais M, Tepperman E, Bernardini MQ, Gien LT, Jimenez W, Murji A. A Multicentre Retrospective Review of clinical characteristics of Uterine Sarcoma. J Obstet Gynaecol Can. 2017;39(8):652–8.
doi: 10.1016/j.jogc.2017.03.090
pubmed: 28729098
Kho KA, Lin K, Hechanova M, Richardson DL. Risk of Occult Uterine Sarcoma in Women undergoing hysterectomy for Benign indications. Obstet Gynecol. 2016;127(3):468–73.
doi: 10.1097/AOG.0000000000001242
pubmed: 26855091
pmcid: 5817881
Bi Q, Xiao Z, Lv F, Liu Y, Zou C, Shen Y. Utility of clinical parameters and multiparametric MRI as predictive factors for differentiating uterine sarcoma from Atypical Leiomyoma. Acad Radiol. 2018;25(8):993–1002.
doi: 10.1016/j.acra.2018.01.002
pubmed: 29422425
Moinfar F, Azodi M, Tavassoli FA. Uterine sarcomas. Pathology. 2007;39(1):55–71.
doi: 10.1080/00313020601136146
pubmed: 17365823
Rojas C, Tian C, Powell MA, Chan JK, Bateman NW, Conrads TP, Rocconi RP, Jones NL, Shriver CD, Hamilton CA, et al. Racial disparities in uterine and ovarian carcinosarcoma: a population-based analysis of treatment and survival. Gynecol Oncol. 2020;157(1):67–77.
doi: 10.1016/j.ygyno.2020.01.017
pubmed: 32029291
Li N, Wu LY, Zhang HT, An JS, Li XG, Ma SK. Treatment options in stage I endometrial stromal sarcoma: a retrospective analysis of 53 cases. Gynecol Oncol. 2008;108(2):306–11.
doi: 10.1016/j.ygyno.2007.10.023
pubmed: 18061249
Huss A, Klar M, Hasanov MF, Juhasz-Boss I, Bossart M. Prognostic factors and survival of patients with uterine sarcoma: a German unicenter analysis. Arch Gynecol Obstet 2022.
Sucu M, Kucukgoz Gulec U, Paydas S, Guzel AB, Kilic Bagir E, Vardar MA. Clinicopathologic characteristics and prognosis comparison of the uterine high grade endometrial carcinomas. Ginekol Pol. 2021;92(4):278–83.
pubmed: 33751504
Cabrera S, Bebia V, Acosta U, Franco-Camps S, Manalich L, Garcia-Jimenez A, Gil-Moreno A. Survival outcomes and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma. Clin Transl Oncol. 2021;23(6):1210–9.
doi: 10.1007/s12094-020-02512-6
pubmed: 33210235
Ayhan A, Gungorduk K, Khatib G, Firat Cuylan Z, Boran N, Gokcu M, Celik H, Ozgul N, Akbayir O, Simsek T, et al. Prognostic factors and survival outcomes of women with uterine leiomyosarcoma: a Turkish uterine Sarcoma Group Study-003. Curr Probl Cancer. 2021;45(5):100712.
doi: 10.1016/j.currproblcancer.2021.100712
pubmed: 33685725
Chantharasamee J, Wong K, Potivongsajarn P, Qorbani A, Motamed N, Brackert S, Cohen J, Chmielowski B, Kalbasi A, Rao J, et al. Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma. Cancer Med. 2022;11(15):2906–12.
doi: 10.1002/cam4.4665
pubmed: 35307963
pmcid: 9359871
Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008;112(4):820–30.
doi: 10.1002/cncr.23245
pubmed: 18189292
Yang H, Li XC, Yao C, Lang JH, Jin HM, Xi MR, Wang G, Wang LW, Hao M, Ding Y, et al. Proportion of uterine malignant tumors in patients with laparoscopic myomectomy: a National Multicenter Study in China. Chin Med J (Engl). 2017;130(22):2661–5.
doi: 10.4103/0366-6999.218008
pubmed: 29133752
Kurjak A, Kupesic S, Shalan H, Jukic S, Kosuta D, Ilijas M. Uterine sarcoma: a report of 10 cases studied by transvaginal color and pulsed Doppler Sonography. Gynecol Oncol. 1995;59(3):342–6.
doi: 10.1006/gyno.1995.9965
pubmed: 8522252
Sun S, Bonaffini PA, Nougaret S, Fournier L, Dohan A, Chong J, Smith J, Addley H, Reinhold C. How to differentiate uterine leiomyosarcoma from leiomyoma with imaging. Diagn Interv Imaging. 2019;100(10):619–34.
doi: 10.1016/j.diii.2019.07.007
pubmed: 31427216
Durnali A, Tokluoglu S, Ozdemir N, Inanc M, Alkis N, Zengin N, Sonmez OU, Kucukoner M. Anatolian Society of Medical O: prognostic factors and treatment outcomes in 93 patients with uterine sarcoma from 4 centers in Turkey. Asian Pac J Cancer Prev. 2012;13(5):1935–41.
doi: 10.7314/APJCP.2012.13.5.1935
pubmed: 22901150
Ishidera Y, Yoshida H, Oi Y, Katayama K, Miyagi E, Hayashi H, Shigeta H. Analysis of uterine corporeal mesenchymal tumors occurring after menopause. BMC Womens Health. 2019;19(1):13.
doi: 10.1186/s12905-019-0714-5
pubmed: 30658711
pmcid: 6339291
Momtahan M, Emami F, Sari Aslani F, Akbarzadeh-Jahromi M. Evaluation of treatment results and prognostic factors of uterine sarcoma: a single-center experience. J Chin Med Assoc. 2020;83(1):84–8.
doi: 10.1097/JCMA.0000000000000188
pubmed: 31517774
Amant F, Mirza MR, Koskas M, Creutzberg CL. Cancer of the corpus uteri. Int J Gynaecol Obstet. 2018;143(Suppl 2):37–50.
doi: 10.1002/ijgo.12612
pubmed: 30306580
Thangappah RBP. Uterine sarcoma: a clinico-pathological study. J Obstet Gynaecol India. 2019;69(Suppl 2):147–52.
doi: 10.1007/s13224-018-1141-5
pubmed: 31686748
Li K, Yin R, Li L, Wang D, Li L, Ma C, Ren Q, Wang G, Fan Y, Zhou H, et al. Diagnosis and treatment of uterine sarcoma: a multicenter, real-world study in western China. Med (Baltim). 2021;100(51):e28220.
doi: 10.1097/MD.0000000000028220
Burghaus S, Halmen S, Gass P, Mehlhorn G, Schrauder MG, Lux MP, Renner SP, Beckmann MW, Hein A, Thiel FC. Outcome and prognosis in uterine sarcoma and malignant mixed mullerian tumor. Arch Gynecol Obstet. 2016;294(2):343–51.
doi: 10.1007/s00404-015-3993-6
pubmed: 26711836
Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989–2007. J Cancer Res Clin Oncol. 2008;134(12):1277–87.
doi: 10.1007/s00432-008-0422-2
pubmed: 18506484
Wang L, Li S, Zhang Z, Jia J, Shan B. Prevalence and occult rates of uterine leiomyosarcoma. Med (Baltim). 2020;99(33):e21766.
doi: 10.1097/MD.0000000000021766
Huss A, Klar M, Hasanov MF, Juhasz-Boss I, Bossart M. Prognostic factors and survival of patients with uterine sarcoma: a German unicenter analysis. Arch Gynecol Obstet. 2023;307(3):927–35.
doi: 10.1007/s00404-022-06515-2
pubmed: 35780401
Nordal RN, Kjorstad KE, Stenwig AE, Trope CG. Leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) of the uterus. A survey of patients treated in the Norwegian Radium Hospital 1976–1985. Int J Gynecol Cancer. 1993;3(2):110–5.
doi: 10.1046/j.1525-1438.1993.03020110.x
pubmed: 11578330
Sizzi O, Manganaro L, Rossetti A, Saldari M, Florio G, Loddo A, Zurawin R, van Herendael B, Djokovic D. Assessing the risk of laparoscopic morcellation of occult uterine sarcomas during hysterectomy and myomectomy: literature review and the ISGE recommendations. Eur J Obstet Gynecol Reprod Biol. 2018;220:30–8.
doi: 10.1016/j.ejogrb.2017.10.030
pubmed: 29149644
Micci F, Heim S, Panagopoulos I. Molecular pathogenesis and prognostication of low-grade’’ and high-grade endometrial stromal sarcoma. Genes Chromosomes Cancer. 2021;60(3):160–7.
doi: 10.1002/gcc.22907
pubmed: 33099834
Kommoss FK, Chang KT, Stichel D, Banito A, Jones DT, Heilig CE, Frohling S, Sahm F, Stenzinger A, Hartmann W, et al. Endometrial stromal sarcomas with BCOR-rearrangement harbor MDM2 amplifications. J Pathol Clin Res. 2020;6(3):178–84.
doi: 10.1002/cjp2.165
pubmed: 32352245
pmcid: 7339170